Publication

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter 12-02-2020
Volume15
Issue 12

Certara to Open New Office in China

The new office will provide the company with opportunities to collaborate more efficiently with customers in the Chinese biopharmaceutical industry.

Certara, a US-based biosimulation company, is opening a new office in Shanghai, China’s Pudong District, a hub for biopharmaceutical research and development.

The new office will provide the company with opportunities to collaborate more efficiently with customers in the Chinese biopharmaceutical industry, a Nov. 9, 2020 company press release said.

“We recognize the tremendous growth of China’s biopharmaceutical industry and are thrilled to have a direct presence in China so that we can fully support our rapidly growing Chinese customer base,” said William F. Feehery, PhD, CEO of Certara, in the press release. “Certara’s extensive experience in biosimulation and our partnerships with top global biopharmaceutical companies will help foster innovation in China, accelerate time-to-market for our customers, and most importantly, improve patient outcomes.”

Source: Certara

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More